{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"In patients continuing beyond 4 cycles the ability to induce complete response will be evaluated at completion of planned therapy.","groups":[{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 15 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 20 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"OG000","title":"Dose Level -1"},{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 20 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 27 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"OG001","title":"Dose Level 0"},{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 20 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 36 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"OG002","title":"Dose Level 1"},{"description":"Patients receive:\n\nOral 300 mg/m\\^2 cyclophosphamide on days 1, 8, and 15;\n\nOral 40 mg dexamethasone on days 1, 8, 15, and 22;\n\nOral 100 mg thalidomide on days 1-28.\n\nPatients also recieve 20 mg/m\\^2 carfilzomib IV on days 1, 2, 8, 9, 15, and 16 in cycle 1, and 45 mg/m\\^2 on days 1, 2, 8, 9, 15, and 16 in subsequent cycles.","id":"OG003","title":"Dose Level 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Following the first 4 courses of treatment","title":"Complete Response (Phase II)","type":"SECONDARY","unitOfMeasure":"participants"}